Serina Therapeutics (SER) EBIT Margin (2018 - 2025)
Serina Therapeutics (SER) posted EBIT Margin of 4280.77% for Q2 2025, down 110.8% sequentially from 39635.71% in Q4 2024, and up 329962.0% YoY from N/an in Q2 2024.
Serina Therapeutics (SER) EBIT Margin (2018 - 2025) Analysis & Trends
Serina Therapeutics has reported EBIT Margin for 8 years, with the latest figure at 4280.77% in Q2 2025.
- Quarterly EBIT Margin rose 329962.0% year-over-year to 4280.77% in Q2 2025, while the trailing twelve-month figure through Dec 2025 was 18478.46% (up 1196440.0% YoY) and the FY2025 annual result came in at 18478.46%, up 1196440.0% from the prior year.
- EBIT Margin slipped to 4280.77% in Q2 2025 per SER's latest filing, from 39635.71% in the prior quarter.
- Over five years, EBIT Margin peaked at 39635.71% in Q4 2024 and troughed at 46420.0% in Q1 2024.
- A 5-year average of 11184.37% and a median of 6975.0% in 2021 frame the typical range for EBIT Margin.
- The widest YoY moves for EBIT Margin: up 3962791 bps in 2024, down 4321333 bps in 2024.
- Over 5 years, EBIT Margin stood at 1166.88% in 2021, then slumped by 1809 bps to 22275.0% in 2022, then jumped by 100 bps to 7.81% in 2023, then jumped by 507599 bps to 39635.71% in 2024, then plunged by 111 bps to 4280.77% in 2025.
- According to Business Quant data, EBIT Margin over the past three periods registered 4280.77%, 39635.71%, and 37942.86% for Q2 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Serina Therapeutics | 45.80 Mn | 22.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -4,280.77% |
| Dec 31, 2024 | 39,635.71% |
| Sep 30, 2024 | -37,942.86% |
| Jun 30, 2024 | -7,580.39% |
| Mar 31, 2024 | -46,420.00% |
| Dec 31, 2023 | 7.81% |
| Sep 30, 2023 | -5,044.83% |
| Jun 30, 2023 | -13,500.00% |
| Mar 31, 2023 | -3,206.67% |
| Dec 31, 2022 | -22,275.00% |
| Sep 30, 2022 | -17,222.22% |
| Jun 30, 2022 | -13,258.33% |
| Mar 31, 2022 | -41,040.00% |
| Dec 31, 2021 | -1,166.88% |
| Sep 30, 2021 | -6,975.00% |
| Jun 30, 2021 | -5,959.46% |
| Mar 31, 2021 | -3,905.36% |
| Dec 31, 2020 | -1,472.78% |
| Sep 30, 2020 | -3,473.91% |
| Jun 30, 2020 | -5,262.22% |